Veradermics reports Phase 3 trial meets all endpoints for oral hair‑loss pill

Veradermics announced on October 19 2026 that its Phase 3 study 304 of VDPHL01 in 536 men with mild‑to‑moderate pattern hair loss met all primary and secondary endpoints. The once‑daily dose increased hair count by 28.6 hairs/cm² and the twice‑daily dose by 36.4 hairs/cm², versus 6.6 hairs/cm² for placebo, and patient‑reported improvement was 78.8% and 85.0% respectively. The company said no treatment‑related serious adverse events occurred and it will evaluate filing the drug for FDA approval.

The company said the data clear a major regulatory hurdle and could make VDPHL01 the first FDA‑approved oral non‑hormonal treatment for male pattern hair loss in nearly 30 years, which may drive significant market adoption. Management noted the strong cash position of about $820 million supports continued development and a potential launch.

  • 1The Phase 3 trial enrolled 536 male participants.
  • 2Hair count increase was 28.6 hairs/cm² for the once‑daily regimen.
  • 3Hair count increase was 36.4 hairs/cm² for the twice‑daily regimen.
  • 4Placebo group hair count increase was 6.6 hairs/cm².
  • 5Patient‑reported improvement was 78.8% (once‑daily) and 85.0% (twice‑daily) versus 35.3% for placebo.
  • 6No treatment‑related serious adverse events were reported.

Sources